Half-year report · HY
6960.TEDINET S100X29Y
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥139.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥64.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥10.7bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.9bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥26.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥11.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥18.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥212.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥221.3bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥204.8bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥39.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥178.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥181.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥172.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥65.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥72.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥60.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥67.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥61.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥13.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥273.47 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥645.41 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥267.34 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 83.6% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Consumables And Other Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.9bn |
| Consumables And Other Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.9bn |
| Consumables And Other Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.7bn |
| Medical Treatment Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.3bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥31.3bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Patient Monitoring Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥574m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥11.1bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥11.1bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥10.7bn |
| Consumables And Other Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| Consumables And Other Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| Consumables And Other Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Medical Treatment Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Patient Monitoring Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥658m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 532
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for product warranties | Prior1YearInstant | 149000000 | JPY |
| Provision for product warranties | InterimInstant | 176000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 3508000000 | JPY |
| Provision for bonuses | InterimInstant | 3137000000 | JPY |
| Other provision cl | Prior1YearInstant | 538000000 | JPY |
| Other provision cl | InterimInstant | 269000000 | JPY |
| Other cl | Prior1YearInstant | 9324000000 | JPY |
| Other cl | InterimInstant | 8246000000 | JPY |
| Current liabilities | Prior1YearInstant | 35219000000 | JPY |
| Current liabilities | InterimInstant | 30098000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 979000000 | JPY |
| Net defined benefit liability | InterimInstant | 1011000000 | JPY |
| Other provision ncl | Prior1YearInstant | 875000000 | JPY |
| Other provision ncl | InterimInstant | 1034000000 | JPY |
| Other ncl | Prior1YearInstant | 2594000000 | JPY |
| Other ncl | InterimInstant | 2726000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 4449000000 | JPY |
| Noncurrent liabilities | InterimInstant | 4772000000 | JPY |
| Liabilities | Prior1YearInstant | 39669000000 | JPY |
| Liabilities | InterimInstant | 34870000000 | JPY |
| Capital stock | Prior1YearInstant | 4621000000 | JPY |
| Capital stock | InterimInstant | 4621000000 | JPY |
| Capital surplus | Prior1YearInstant | 17506000000 | JPY |
| Capital surplus | InterimInstant | 17840000000 | JPY |
| Retained earnings | Prior1YearInstant | 180440000000 | JPY |
| Retained earnings | InterimInstant | 184820000000 | JPY |
| Treasury stock | Prior1YearInstant | -27258000000 | JPY |
| Treasury stock | InterimInstant | -37324000000 | JPY |
| Shareholders equity | Prior1YearInstant | 175309000000 | JPY |
| Shareholders equity | InterimInstant | 169957000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 4591000000 | JPY |
| Valuation difference on available for sale securities | InterimInstant | 6461000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 572000000 | JPY |
| Foreign currency translation adjustment | InterimInstant | 586000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 1179000000 | JPY |
| Remeasurements of defined benefit plans | InterimInstant | 1057000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 6343000000 | JPY |
| Valuation and translation adjustments | InterimInstant | 8105000000 | JPY |
| Net assets | Prior1YearInstant | 181652000000 | JPY |
| Net assets | InterimInstant | 178063000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 221321000000 | JPY |
| Liabilities and net assets | InterimInstant | 212934000000 | JPY |
| Net sales | Prior1InterimDuration | 64314000000 | JPY |
| Net sales | InterimDuration | 64807000000 | JPY |
| Cost of sales | Prior1InterimDuration | 30533000000 | JPY |
| Cost of sales | InterimDuration | 29330000000 | JPY |
| Gross profit | Prior1InterimDuration | 33780000000 | JPY |
| Gross profit | InterimDuration | 35476000000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 23125000000 | JPY |
| Selling general and administrative expenses | InterimDuration | 24813000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |